Harvard Bioscience

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. It operates under the geographical segments: United States, Germany, United Kingdom, and Rest of the world. It sells its products through catalog, Website, distributors, and direct sales force. The company was founded by Dr. William T. Porter in 1901 and is headquartered in Holliston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Harvard Bioscience reports strong Q4 earnings, eyes China growth

Harvard Bioscience delivered solid financial performance in Q4 2022 with revenue growth and strong margins.
The company faces challenges in supply chain issues and debt reduction but is focused on growth opportunities.
Strategic plans for new product development and improving gross margins are key priorities for future success.

Harvard Bioscience reports strong Q1 earnings, eyes growth opportunities

Harvard Bioscience delivered solid Q1 2023 results with revenue growth, improved margins, and enhanced profitability. While facing challenges in sales organization and market shifts, the company is strategically positioned to capitalize on opportunities for growth through new product offerings and operational efficiencies.

Harvard Bioscience reports mixed Q2 results, eyes growth opportunities

Harvard Bioscience's Q2 2023 performance showed slight revenue decline but notable improvements in margins and profitability.
The company's strengths include new product launches, positive financial metrics, and a promising revenue guidance for 2023.
Challenges include managing discontinued products impact, sales force effectiveness, and profitability.
Opportunities exist in leveraging new products, addressing challenges, and optimizing financial performance drivers.

Harvard Bioscience reports improved margins and profitability in Q3

Harvard Bioscience (HBIO) showed mixed performance in Q3 2023 with revenue decline but improved margins and profitability. The company aims to sustain growth through new product launches and service expansion while managing debt effectively.

Harvard Bioscience reports Q4 results, eyes growth through new products

Harvard Bioscience reported mixed Q4 2023 results with revenue decline in some regions.
The company aims for long-term growth through new products and market expansion.
Challenges include revenue decline in certain regions and maintaining/improving margins.
Opportunities lie in new product launches, partnerships, and market expansion strategies.

Harvard Bioscience faces Q1 revenue dip, eyes second-half turnaround

Harvard Bioscience navigated a tough Q1 marked by revenue declines in key regions and operational challenges. However, the company's focus on new product launches and efficiency in maintaining a strong gross margin are positive indicators. Looking ahead, Harvard Bioscience anticipates a turnaround in the second half of the year with improved margins and overall performance.

Harvard Bioscience reports Q3 revenue decline, eyes growth opportunities

Harvard Bioscience faced revenue decline in Q3 due to China and Asia Pacific weakness but expects stabilization and growth.
Operational improvements and cost reductions are enhancing efficiency and profitability.
New product launches and focus on high-growth areas position the company for incremental growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Harvard Bioscience (HBIO) delivered earnings and revenue surprises of 0.00% and 5.56%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Harvard Bioscience (HBIO) Q3 Earnings Meet Estimates

Strong double digit revenue growth, solid margin performance despite global supply chain disruptions

Harvard Bioscience Announces Third Quarter 2021 Financial Results

Harvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Harvard Bioscience (HBIO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

HOLLISTON, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for third quarter ended September 30, 2021, before the market opens on November 3, 2021, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

Harvard Bioscience Schedules Third Quarter 2021 Earnings Conference Call for November 3, 2021 at 8:00 AM ET

American Express

Cisco Systems

Goldman Sachs

Home Depot

Honeywell

Johnson & Johnson

JPMorgan Chase & Co

Microsoft

Procter & Gamble

Silvergate Capital Corp

Visa

Two new Breakout Stocks for Week 32 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. Following the Momentum Gauges®, the portfolio is up +49.8% YTD with a record 18 out of 32 weeks this year in negative market conditions above the 40 MG level.

Week 33 MDA Breakout Stocks - August 2021: Short-Term Picks To Give You An Edge

Harvard Bioscience, Inc. (HBIO) CEO James Green on Q2 2021 Results - Earnings Call Transcript

Harvard Bioscience (HBIO) delivered earnings and revenue surprises of 20.00% and 6.56%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Harvard Bioscience (HBIO) Tops Q2 Earnings and Revenue Estimates

Harvard Bioscience Announces Second Quarter 2021 Financial Results

Harvard Bioscience (HBIO) Reports Next Week: What to Know Ahead of the Release

HOLLISTON, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for second quarter ended June 30, 2021 before the market opens on August 5, 2021, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

Harvard Bioscience Schedules Second Quarter 2021 Earnings Conference Call for August 5, 2021 at 8:00 AM ET

Does Harvard Bioscience (HBIO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Harvard Bioscience (HBIO) is a Great Choice

Harvard Bioscience (HBIO) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Harvard Bioscience (HBIO) Is a Great Choice for "Trend" Investors, Here's Why

Duluth Hlds

Genco Shipping & Trading

Velocity Financial

The logic behind this strategy for stock selection is to identify stocks that are trading within a narrow band.

4 Breakout Stocks You Must Add Right Away to Your Portfolio

Barnes & Noble Education

Casper Sleep

SmileDirectClub

Sirius XM Holdings Inc

Truecar Inc

Value investors look for inexpensive stocks that have growth potential. They often see low cost stocks as being on sale or undervalued.

7 Stocks To Buy Right Now Under $10

Alpha and Omega Semiconductor

ArcBest

LGI Homes

Textainer Group Holdings Limited

This is probably the time to focus on fundamentals because we don't want to overpay for stocks in a buoyant market.

5 Stocks with Solid Track Records at Attractive Prices

Harvard Bioscience (HBIO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Surging Earnings Estimates Signal Upside for Harvard Bioscience (HBIO) Stock

Harvard Bioscience, Inc. (HBIO) CEO James Green on Q1 2021 Results - Earnings Call Transcript

Harvard Bioscience (HBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Harvard Bioscience (HBIO) Soars 8.3%: Is Further Upside Left in the Stock?

Harvard Bioscience (HBIO) delivered earnings and revenue surprises of 66.67% and 6.68%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Harvard Bioscience (HBIO) Tops Q1 Earnings and Revenue Estimates

Sales effectiveness, pre-clinical product demand and disciplined cost management result in improved revenues and margins

Harvard Bioscience Announces First Quarter 2021 Financial Results

HOLLISTON, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for first quarter ended March 31, 2021 before the market opens on May 6, 2021, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

Harvard Bioscience Schedules First Quarter 2021 Earnings Conference Call for May 6, 2021 at 8:00 AM ET

Harvard Bioscience, Inc. (HBIO) CEO Jim Green on Q4 2020 Results - Earnings Call Transcript

Shares of Harvard Bioscience (NASDAQ:HBIO) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share increased 0.00% year over year to $0.08, which beat the estimate of $0.06.

Harvard Bioscience: Q4 Earnings Insights

On Wednesday, March 10, Harvard Bioscience (NASDAQ:HBIO) will release its latest earnings report. Decipher the announcement with Benzinga's help.

Preview: Harvard Bioscience's Earnings

HOLLISTON, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for fourth quarter ended December 31, 2020 before the market opens on March 10, 2021, and will hold a conference call to discuss the results on March 10, 2021 at 8:00 a.m. Eastern Time.

News for Harvard Bioscience Stock (HBIO)